Blood Plasma Market Growth Opportunities & Forecast [2031]
Blood Plasma Market Growth Opportunities & Forecast [2031]
Segments - Blood Plasma Market by Blood Type (Factor VIII, Immunoglobulin, Anti-inhibitor Coagulation Factor, Rh Immunoglobulin, Albumin, Anti-Thrombin, and Factor IX), Application (Immunodeficiency Diseases, Bleeding Disorders, Hemophilia, Genetic Lung Disorders, Liver Conditions, Viral Disease, and Immune Deficiency System), End-user (Academic Institutions, Hospitals, Clinics, and Research Laboratories), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-5159
| 4.1 Rating
| 81 Reviews
| 176 Pages
| Format :
Report Description
The global blood plasma market size was, USD 31.38 Bn in 2022 and is estimated to reach USD 98.38 Bn by 2031, expanding at a CAGR of 6.7% during 2023–2031. Rising number of blood disorders and growing awareness about hemophilia are expected to fuel the market.
Light yellow-colored liquid portion of blood, which contains protein and other constituents of whole blood where blood cells are absent is known as blood plasma. Blood plasma possesses more than 100 proteins and plays an important role in exchanging minerals and maintaining blood pressure. Plasma is collected through a process of blood collection.
Blood plasma is widely used as a major ingredient in various types of medical products. It replaces antibodies, body fuels, and clotting factors. Plasma carries potassium and sodium to the muscles, which is the electrolyte. The electrolytes help in contracting muscles and keep the human body hydrated.
Blood plasma maintains the PH of the human body, which improves cell function. It provides a liquid base for blood. Blood plasma contains 92% of water. It takes hormones, nutrients, and proteins to the different parts of the body. Cells excrete their waste into the plasma, which in turn, helps in removing it from the human body.
Plasma donation depends upon the blood type. Type AB plasma, considered a universal plasma, has an immediate transfusion without losing important time determining if the patient’s blood type is compatible. Plasma provides water all over the body parts whenever the body needs it. Plasma supports the blood vessels from collapsing. According to American Red Cross, people donate plasma up to 13 times yearly and every 28 days.
The COVID-19 pandemic propelled the blood plasma market. In August 2020, the Food and Drug Administration (FDA) approved and gave an emergency use authorization (EAU) for supporting the treatment for hospitalized patients with the pandemic.
Blood Plasma Market Dynamics
Major Drivers
Rising number of severe blood disorders such as hemophilia, thalassemia, and other diseases are driving the blood plasma market. Increasing approval rate of blood plasma products for emergency treatment in COVID-19 is driving the market.
Growing number of people donating blood and blood plasma to help others recover from various illnesses, which in turn, is propelling the market. Increasing use of blood plasma to treat disorders such as leukemia, types of lymphoma, hemophilia, and malignancies is projected to drive the market. Moreover, high usage of albumin in therapeutic areas and the increasing geriatric population and geriatric medicine are boosting the blood plasma market.
Existing Restraints
High prices of blood plasma treatments and the spread of other pathogenic containments hinder the market. Awareness about the rare side effects such as citrate reaction is projected to hamper the market.
Government restrictions on plasma donation can restrain the market. For instance, the weight of a plasma donor needs to be 110 pounds or 50 kilograms. Plasma donors must pass a medical exam. Thus impeding the market.
Emerging Opportunities
Technology advancement in blood plasma collection and plasma process, and rising demand for plasma therapies due to the ageing population is a major opportunity for blood plasma market investors and healthcare companies. Increasing demand for advanced blood plasma products creates a lucrative opportunity for market players during the forecast period. Moreover, rising clinical studies for the safety and efficacy of a vast range of therapeutic drugs positively is expected to boost the market.
PID is a condition where the human body’s immune system does not function correctly, making humans more susceptible to infections. Blood plasma therapy is used to help patients with PID by providing antibodies to fight off infectious. Increasing R&D activities to develop advanced-level plasma-derived products is projected to create lucrative opportunities in the global blood plasma market.
Scope of Blood Plasma Market Report
The market report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Blood Plasma Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Blood Type (Factor VIII, Immunoglobulin, Anti-inhibitor Coagulation Factor, Rh Immunoglobulin, Albumin, Anti-Thrombin, and Factor IX), Application (Immunodeficiency Diseases, Bleeding Disorders, Hemophilia, Genetic Lung Disorders, Liver Conditions, Viral Disease, and Immune Deficiency System), and End-user (Academic Institutions, Hospitals, Clinics, and Research Laboratories) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Pfizer Inc; AbbVie Inc; ADMA Biologics ,inc; Revance; USWM, LLC; Ipsen Pharma; Evolus;Merz Pharma; Merz Pharma; GlaxoSmithKline plc; Biotest AG; and HUGEL, Inc |
Blood Plasma Market Segment Insights
Based on blood type, the blood plasma market is divided into factor viii, immunoglobulin, anti-inhibitor coagulation factor, rh immunoglobulin, albumin, anti-thrombin, and factor ix. The immunoglobulin segment is expected to expand at a significant pace during the projection period. Immunoglobin is also called as antibodies, which help recover from blood disorders. Immunoglobin is used as an antibody across the globe, which in turn, drives the segment.
On the basis of application, the global market is segregated into immunodeficiency diseases, bleeding disorders, hemophilia, genetic lung disorders, liver conditions, viral diseases, and immune deficiency system. The hemophilia segment is projected to expand at a considerable CAGR during the forecast period. Increase in research & development activities on hemophilia for the recovery of early stages patients drives the segment.
In terms of end-user, the blood plasma market is categorized as academic institutions, hospitals, clinics, and research laboratories. The hospitals segment is expected to register a robust pace during the forecast period. Convalescent plasma therapy is rapidly used in hospitals for rapid recovery of patients.
Based on region, the global blood plasma market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to dominate the market during the projection period due to the increasing geriatric population, high disposable income, and rising development in biomedical technologies. Additionally, presence of a well-established healthcare sector and rapid adoption of technology in North America are fueling the market in the region. The market in Europe is projected to expand rapidly due to the increasing focus on R&D.
Segments
The global blood plasma market has been segmented on the basis of
Blood Type
- Factor VIII
- Immunoglobulin
- Anti-inhibitor Coagulation Factor
- Rh Immunoglobulin
- Albumin
- Anti-Thrombin
- Factor IX
Application
- Immunodeficiency Diseases
- Bleeding Disorders
- Hemophilia
- Genetic Lung Disorders
- Liver Conditions
- Viral Disease
- Immune Deficiency System
End-user
- Academic Institutions
- Hospitals
- Clinics
- Research Laboratories
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Pfizer Inc
- AbbVie Inc
- ADMA Biologics, Inc
- Revance
- USWM, LLC
- Ipsen Pharma
- Evolus
- Merz Pharma
- GlaxoSmithKline plc
- Biotest AG
- HUGEL, Inc
Competitive Landscape
Key players competing in the global blood plasma market Pfizer Inc; AbbVie Inc; ADMA Biologics inc; Revance; USWM, LLC; Ipsen Pharma; Evolus; Merz Pharma; GlaxoSmithKline plc; Biotest AG; and HUGEL, Inc. These players adopt various strategies including product launches, acquisitions, collaboration, mergers, and partnerships to increase their market share.
- In March 2019, Biotest AG acknowledged the approval for the abridged solvent volume by half for the Factor VIII concentrate haemoctinR SDH in thirteen countries in Europe.
- In January 2020, ADMA Biologics entered to sell and produce a plasma-derived transitional factor in supply and manufacture.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Blood Plasma Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Blood Plasma Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Blood Plasma Market - Supply Chain
4.5. Global Blood Plasma Market Forecast
4.5.1. Blood Plasma Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Blood Plasma Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Blood Plasma Market Absolute $ Opportunity
5. Global Blood Plasma Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Blood Plasma Market Size and Volume Forecast by Applications
5.3.1. Immunodeficiency Diseases
5.3.2. Bleeding Disorders
5.3.3. Hemophilia
5.3.4. Genetic Lung Disorders
5.3.5. Liver Conditions
5.3.6. Viral Disease
5.3.7. Immune Deficiency System
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Blood Plasma Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Blood Plasma Market Size and Volume Forecast by End Users
6.3.1. Academic Institutions
6.3.2. Hospitals
6.3.3. Clinics
6.3.4. Research Laboratories
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Blood Plasma Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Blood Plasma Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Blood Plasma Demand Share Forecast, 2019-2026
8. North America Blood Plasma Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Blood Plasma Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Blood Plasma Market Size and Volume Forecast by Applications
8.4.1. Immunodeficiency Diseases
8.4.2. Bleeding Disorders
8.4.3. Hemophilia
8.4.4. Genetic Lung Disorders
8.4.5. Liver Conditions
8.4.6. Viral Disease
8.4.7. Immune Deficiency System
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. North America Blood Plasma Market Size and Volume Forecast by End Users
8.7.1. Academic Institutions
8.7.2. Hospitals
8.7.3. Clinics
8.7.4. Research Laboratories
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Blood Plasma Demand Share Forecast, 2019-2026
9. Latin America Blood Plasma Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Blood Plasma Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Blood Plasma Market Size and Volume Forecast by Applications
9.4.1. Immunodeficiency Diseases
9.4.2. Bleeding Disorders
9.4.3. Hemophilia
9.4.4. Genetic Lung Disorders
9.4.5. Liver Conditions
9.4.6. Viral Disease
9.4.7. Immune Deficiency System
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Latin America Blood Plasma Market Size and Volume Forecast by End Users
9.7.1. Academic Institutions
9.7.2. Hospitals
9.7.3. Clinics
9.7.4. Research Laboratories
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Blood Plasma Demand Share Forecast, 2019-2026
10. Europe Blood Plasma Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Blood Plasma Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Blood Plasma Market Size and Volume Forecast by Applications
10.4.1. Immunodeficiency Diseases
10.4.2. Bleeding Disorders
10.4.3. Hemophilia
10.4.4. Genetic Lung Disorders
10.4.5. Liver Conditions
10.4.6. Viral Disease
10.4.7. Immune Deficiency System
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Europe Blood Plasma Market Size and Volume Forecast by End Users
10.7.1. Academic Institutions
10.7.2. Hospitals
10.7.3. Clinics
10.7.4. Research Laboratories
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Blood Plasma Demand Share Forecast, 2019-2026
11. Asia Pacific Blood Plasma Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Blood Plasma Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Blood Plasma Market Size and Volume Forecast by Applications
11.4.1. Immunodeficiency Diseases
11.4.2. Bleeding Disorders
11.4.3. Hemophilia
11.4.4. Genetic Lung Disorders
11.4.5. Liver Conditions
11.4.6. Viral Disease
11.4.7. Immune Deficiency System
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Asia Pacific Blood Plasma Market Size and Volume Forecast by End Users
11.7.1. Academic Institutions
11.7.2. Hospitals
11.7.3. Clinics
11.7.4. Research Laboratories
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Blood Plasma Demand Share Forecast, 2019-2026
12. Middle East & Africa Blood Plasma Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Blood Plasma Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Blood Plasma Market Size and Volume Forecast by Applications
12.4.1. Immunodeficiency Diseases
12.4.2. Bleeding Disorders
12.4.3. Hemophilia
12.4.4. Genetic Lung Disorders
12.4.5. Liver Conditions
12.4.6. Viral Disease
12.4.7. Immune Deficiency System
12.5. Basis Point Share (BPS) Analysis by Applications
12.6. Y-o-Y Growth Projections by Applications
12.7. Middle East & Africa Blood Plasma Market Size and Volume Forecast by End Users
12.7.1. Academic Institutions
12.7.2. Hospitals
12.7.3. Clinics
12.7.4. Research Laboratories
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Blood Plasma Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Blood Plasma Market: Market Share Analysis
13.2. Blood Plasma Distributors and Customers
13.3. Blood Plasma Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Pfizer Inc
13.4.2. AbbVie Inc
13.4.3. ADMA Biologics, Inc
13.4.4. Revance
13.4.5. USWM, LLC
13.4.6. Ipsen Pharma
13.4.7. Evolus
13.4.8. Merz Pharma
13.4.9. GlaxoSmithKline plc
13.4.10. Biotest AG
13.4.11. HUGEL, Inc
Methodology
Related Reports
Some other reports from this category!
Our Clients
